iTeos Therapeutics, Inc.

Report data for EOS-448 and IMID trial in multiple myeloma

Deadline passed; outcome being checked

Announced: 11 Jan 2021
Due: 30 Jun 2022
Status: Checking

Deadline
Met
Late
Not met
Today

What the company said

“Mid 2022”

SourceiTeos Therapeutics, Inc. Form 8-K press release, 2021-01-11
FilingSEC filing index
Deadline as statedMid 2022
Deadline used30 Jun 2022, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2021-C808865-021559
Cite as https://keptindex.org/c/KI-C-2021-C808865-021559/ — this address never changes.

What we found

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: EOS-448 and IMID trial data
In the company’s control: Medium
Specificity: High
Depends on: Regulatory, Customer

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you iTeos Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-C808865-021559 · Corrections policy